Testosterone May Slow Glioblastoma in Men and TRT Implications

Estimated reading time: 9 minutes

Key takeaways

• Early 2026 data from an NIH-funded Cleveland Clinic team, published in Nature, indicate that loss of testosterone accelerates glioblastoma growth in male mice by shifting brain-immune dynamics; this effect was not seen in females.
• In human observational data, men with glioblastoma who were already receiving prescribed testosterone (for reasons unrelated to cancer) had lower mortality risk and longer median survival than matched controls. This is correlation, not proof of causation.
• The research does not justify starting, stopping, or changing TRT to treat a brain tumor. Standard-of-care glioblastoma treatments remain unchanged.
• For men with confirmed hypogonadism, TRT remains FDA-approved with known risks and monitoring needs (notably blood pressure and hematocrit). Any use alongside brain cancer care should be coordinated by an experienced oncology and endocrine team.
• Open questions include whether randomized trials will confirm a survival benefit, how testosterone interacts with temozolomide, radiation, and dexamethasone, and how to optimize dosing in this context.

Early data suggest testosterone may help restrain glioblastoma growth in men. Here’s what that could mean for TRT decisions, safety, and care coordination.

What the new Cleveland Clinic study found

In May 2026, Cleveland Clinic researchers reported that testosterone appears to suppress glioblastoma in males. In male preclinical models, depriving animals of testosterone sped up tumor growth and altered the brain’s immune environment in ways that favored the tumor. The same pattern did not hold in females, suggesting a distinctly male-specific biology at play.

The NIH highlighted the study’s importance because it challenges a long-standing narrative: that male sex hormones likely worsen aggressive cancers like glioblastoma. Men have historically had higher incidence and poorer outcomes with glioblastoma than women, which reinforced the belief that androgens were part of the problem. The new data suggest the opposite could be true for the male brain—testosterone may help restrain tumor progression by shaping immune and inflammatory pathways.

For readers following “testosterone brain tumor” research, this is a genuine pivot point: strong preclinical evidence in males, with a mechanistic rationale that lines up with observed sex differences.

Testosterone, brain tumors, and what the human data show—and don’t show

The team also examined population-level outcomes using U.S. registry data. In a SEER analysis of more than 1,300 men with glioblastoma (2008–2019), those who had been prescribed testosterone for non-cancer reasons showed a 38% lower risk of death compared with matched peers not on testosterone. Median survival was roughly 16 months in the testosterone group versus 12 months with standard chemotherapy alone.

That said, observational data cannot prove testosterone caused the improved outcomes. Men on TRT may differ in ways the registry cannot fully capture (for example, overall health status, access to specialty care, or fitness). The analysis nonetheless adds a clinically relevant signal that aligns with the male-specific preclinical biology.

The bottom line: intriguing association, not a practice-changing conclusion. Randomized controlled trials are needed to determine whether testosterone meaningfully improves survival and how it should be used alongside standard glioblastoma therapy—if at all.

Why this is surprising—and how the new picture fits

For years, clinicians generalized from other cancer settings (like prostate cancer) where androgens can fuel tumor growth. Because glioblastoma outcomes are worse in men, many assumed male hormones contributed to that gap.

The 2026 findings paint a more nuanced picture: in male brains, testosterone may calibrate immune and inflammatory responses in ways that reduce a tumor’s ability to thrive. When testosterone drops, the tumor microenvironment appears to become more permissive—more inflammatory in the wrong ways and more immunosuppressive where it matters—allowing the cancer to expand.

This sex-specific effect underscores a broader lesson in oncology and endocrinology: the same hormone can have opposite implications depending on tissue type, disease context, and sex.

Practical implications if you’re considering or already on TRT

If you are a man living with glioblastoma and also meet criteria for hypogonadism, or if you’re already receiving TRT for clinically confirmed low testosterone, here are considerations to discuss with your care team:

• Do not start, stop, or adjust testosterone as an anti-cancer strategy without oncology guidance. Despite the promising signal, there are no randomized trials confirming a survival benefit or defining safe use with temozolomide, radiation, or dexamethasone.
• TRT’s current role is unchanged: It is FDA-approved for men with clinical hypogonadism, typically diagnosed with symptoms plus repeatedly low morning testosterone levels. It is not approved for age-related low testosterone alone.
• Safety updates matter. The FDA revised testosterone labeling in 2025, removing the prior boxed warning about major cardiovascular risk while adding clearer warnings about blood pressure increases. Hematocrit elevation and prostate monitoring remain standard considerations across formulations.
• Monitoring remains essential. If you and your clinician decide that TRT is appropriate for hypogonadism, expect regular checks of blood pressure, hematocrit/hemoglobin, lipids, PSA and prostate health (as indicated), liver function (per product), and symptom response.
• Cancer care coordination is key. Potential interactions with corticosteroids (like dexamethasone), antiepileptics, and chemotherapy agents deserve individualized review. The brain-tumor context brings unique pharmacologic and physiologic dynamics.
• Lifestyle still matters. Sleep, nutrition, resistance training, and management of metabolic risk can support quality of life and lean mass, whether or not you use TRT. If you’re on GLP-1 therapy for weight management, discuss testosterone testing with your clinician; maintaining lean mass can be challenging during rapid weight loss.

For men searching “TRT glioblastoma” or “testosterone brain tumor,” the pragmatic message today is caution with optimism: there may be a benefit, but it has not yet been proven or integrated into guidelines.

How could testosterone suppress glioblastoma in males?

Mechanistically, the study proposes that testosterone helps maintain a brain-immune balance in males that is less favorable to glioblastoma growth. When testosterone is depleted, the tumor microenvironment shifts:

• Inflammation becomes dysregulated, driving tumor-supportive signals rather than effective anti-tumor surveillance.
• Immune activity within the brain tilts toward an immunosuppressive state that allows glioblastoma cells to expand.

These findings do not imply that “more is better.” Hormones exist on a spectrum where both deficiency and excess can carry risks. Any potential therapeutic window will need to be defined carefully in clinical trials, with attention to dosing, timing, and interactions with standard treatments.

What this does not mean

• It does not mean testosterone treats brain cancer. No clinical trial has established testosterone as a therapy for glioblastoma.
• It does not mean androgen deprivation (useful in other cancers) is advisable in brain tumors. The male-specific preclinical data suggest the opposite—but clinical confirmation is needed.
• It does not apply to women. The key effects were observed in males; the female brain-tumor biology in this context appears different.
• It does not endorse high-dose or unsupervised hormone use. Supraphysiologic androgens are not the same as guideline-directed TRT and may present distinct risks.

Questions to bring to your oncology and endocrine teams

• Given my diagnosis and labs, do I meet criteria for hypogonadism that would justify TRT on its own merits?
• If I’m already on TRT, should I continue during glioblastoma treatment? How will we coordinate monitoring?
• Could testosterone interact with my current regimen (temozolomide, radiation, dexamethasone, antiepileptics)? What signs would prompt a change?
• What targets will we use for testosterone levels, and how often will we measure hematocrit, blood pressure, and PSA?
• Are there clinical trials near me evaluating testosterone or hormone modulation in glioblastoma?
• If TRT is not appropriate, what non-hormonal strategies can support energy, mood, lean mass, and sexual health during treatment?

What to watch next: trials, timelines, and safety signals

The NIH has called attention to these findings and the need for clinical trials. Here’s what to expect as research progresses:

• Pilot studies may first test feasibility and safety of physiologic testosterone replacement in hypogonadal men with glioblastoma, closely tracking tumor response and quality of life.
• Larger randomized controlled trials would be needed to assess survival endpoints and define any additive benefit with standard-of-care therapy.
• Safety analyses will focus on cardiovascular events, blood pressure changes, erythrocytosis, prostate outcomes, and neurologic status—in the specific context of brain cancer care.
• Regulatory guidance has not changed. Until trial data mature and are reviewed, TRT should be used for established indications, not as a cancer therapy.

For Taurus Meds patients: our approach to TRT in complex cases

At Taurus Meds, we follow an evidence-informed, safety-first model:

• We prescribe TRT only for clinically confirmed hypogonadism, not for performance enhancement or as a cancer treatment.
• We coordinate with oncology, neurology, and primary care when patients have active or recent cancers, ensuring shared decision-making and clear monitoring plans.
• We follow FDA guidance on blood pressure risk and hematologic monitoring across formulations, and we personalize schedules for labs and follow-up.
• We remain engaged with emerging research and will adapt protocols as high-quality evidence develops.

If you’re a current patient with a brain tumor diagnosis—or you’re considering TRT and worried about how hormones intersect with brain health—bring these questions to your Taurus Meds clinician. We’ll review your goals, labs, and overall plan alongside your oncology team.

Conclusion

The latest evidence suggests a paradigm shift: in males, testosterone may help suppress glioblastoma growth—at least in preclinical models—and existing human data hint at a survival advantage among men already on prescribed testosterone. That’s encouraging, but it’s not a clinical directive. There are no trials yet proving that adding or maintaining TRT improves brain tumor outcomes, and there are important safety and coordination questions to resolve.

For now, the practical path is straightforward: use TRT for the right reasons (documented hypogonadism), under careful monitoring, and in full coordination with your cancer team. Stay tuned as trials clarify whether this male-specific biology can translate into better, evidence-based care.

Disclaimer

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Do not start, stop, or change any medication—including testosterone—without guidance from your licensed healthcare providers.

Sources

• American Bazaar coverage of the NIH-funded study
• NIH news release on testosterone and glioblastoma
• FDA testosterone information